Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
NCT07122076Phase 1Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT719 in systemic lupus erythematosus (SLE), inflammatory myopathy (IIM) and systemic sclerosis (SSc), sponsored by Grit Biotechnology. Primary endpoints: Proportion of participants experiencing dose limiting toxicity at 28 days and Incidence of treatment-emergent adverse events at 3 months. Started Aug 2025; status: recruiting.
02
Drugs
GT719
03
Conditions
systemic lupus erythematosus (SLE)inflammatory myopathy (IIM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07122076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122076.